ArriVent BioPharma (NASDAQ:AVBP) Releases Quarterly Earnings Results, Beats Expectations By $0.23 EPS

ArriVent BioPharma (NASDAQ:AVBP) released its earnings results on Monday. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.23, FiscalAI reports. The company had revenue of $5.00 million during the quarter, compared to the consensus estimate of $0.80 million.

ArriVent BioPharma Stock Up 3.8%

Shares of NASDAQ:AVBP traded up $0.52 on Monday, reaching $14.16. 905,956 shares of the company’s stock were exchanged, compared to its average volume of 746,557. The business’s 50-day moving average is $23.05 and its two-hundred day moving average is $26.66. ArriVent BioPharma has a fifty-two week low of $11.36 and a fifty-two week high of $35.83. The firm has a market capitalization of $698.20 million, a price-to-earnings ratio of -3.91 and a beta of 1.66.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of ArriVent BioPharma in a research note on Tuesday, September 22nd. JonesTrading cut their price objective on ArriVent BioPharma from $45.00 to $22.00 and set a “buy” rating on the stock in a research note on Wednesday, October 7th. BTIG Research reaffirmed a “buy” rating and set a $29.00 target price on shares of ArriVent BioPharma in a report on Friday, October 16th. Truist Financial set a $21.00 target price on ArriVent BioPharma in a report on Monday, October 26th. Finally, HC Wainwright decreased their target price on ArriVent BioPharma from $47.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, October 8th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.56.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision oncology therapies for patients with genetically defined cancers. The company’s primary focus is on targeted treatments for non-small cell lung cancer (NSCLC), particularly tumors driven by mutations in the epidermal growth factor receptor (EGFR) gene.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible EGFR tyrosine kinase inhibitor designed to target a range of EGFR mutations, including common mutations and exon 20 insertion mutations.